Screener
Novavax NVAX SG&A
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Expenses: | ||||
| Cost of sales | 14,246 | 15,325 | 44,941 | 29,439 |
| Research and development | 70,693 | 79,233 | 166,165 | 168,170 |
| Selling, general, and administrative | 26,665 | 43,612 | 55,442 | 91,702 |
| Total expenses | 111,604 | 138,170 | 266,548 | 289,311 |
| Income (loss) from operations | (54,906) | 101,070 | (70,336) | 616,584 |
| Other income (expense): | ||||
| Interest expense | (5,689) | (5,518) | (10,590) | (11,241) |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's SG&A?
- Novavax (NVAX) reported SG&A of $26.67M in Q2 2026.
- How has Novavax's SG&A changed year-over-year?
- Novavax's SG&A decreased by 38.9% year-over-year, from $43.61M to $26.67M.
- What is the long-term trend for Novavax's SG&A?
- Over 2 years (2022 to 2025), Novavax's SG&A has grown at a -43.2% compound annual growth rate (CAGR), from $488.69M to $157.48M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Novavax's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude